Fenofibrate - First Lipid Modifying Agent Shown to Protect Diabetic Eye

2007-11-08 07:35 547

SYDNEY, Australia, Nov. 8 /Xinhua-PRNewswire/ --

In the Lancet, on Tuesday, November, 6th new results of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) 2007 clinical trial have been published and presented on the same date at a press conference held during the AHA.

- First lipid modifying agent shown to reduce the need for treatment of

the leading causes of blindness and deteriorating vision in patients

with type 2 diabetes

- Reduces need for laser treatment in patients with and without known

diabetic retinopathy

- Significantly decreases progression of diabetic eye disease

If you are interested in knowing more about this breaking news

and in getting additional information on the management of microvascular

complications in type 2 diabetes, we are pleased to invite you to visit "the

Field Study Investigators Website," where you will have the opportunity to

login to the Webcast of the press conference.

Please click below:

Source: NHMRC; The University of Sydney